TCL1: a new drug target in lymphoid and germ-cell malignancies?
The protein product of the T-cell leukemia/lymphoma 1 (TCL1) oncogene was recently identified as a novel Akt kinase activator. Its crystal structure predicts regions most likely involved in protein-protein interactions, and complex formation is required for TCL1 to activate Akt. TCL1 is expressed in a broad range of normal and malignant lymphoid cell types and in a high proportion of testicular seminomas of germ cell origin, indicating its potential to serve as a novel anti-cancer drug target. This review is focused on the current state of knowledge of TCL1 and the medical implications of its discovery.
Lock
Richard B
RB
Children's Cancer Institute Australia for Medical Research, NSW 2031, Randwick, Australia. richard.lock@unsw.edu.au
D000818:Animals; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D004789:Enzyme Activation; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008954:Models, Biological; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt; D018239:Seminoma / Q000188:drug therapy* / Q000276:immunology; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000276:immunology; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*
D004268:DNA-Binding Proteins; D011518:Proto-Oncogene Proteins; C090851:TCL1A protein, human; D014157:Transcription Factors; C494918:AKT1 protein, human; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt